Business Context and Reporting Period
This Form 6-K filing by Redhill Biopharma Ltd. (Nasdaq: RDHL) covers the period ending September 22, 2023. The company is a specialty biopharmaceutical firm focused on gastrointestinal and infectious diseases, with marketed products including Talicia and Aemcolo, and a pipeline of late-stage clinical candidates such as opaganib and RHB-107.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose a regulatory notification regarding stock listing compliance rather than to present financial performance data.
Material Changes and Listing Deficiencies
- Minimum Bid Price Deficiency: On September 19, 2023, Nasdaq notified Redhill that its ADS bid price closed below the $1.00 minimum requirement for 30 consecutive business days (August 7 to September 18, 2023).
- Compliance Period: The company has an initial 180-day period, until March 18, 2024, to regain compliance by maintaining a closing bid price of $1.00 or more for 10 consecutive business days.
- Market Value of Publicly Held Shares (MVPHS): The company remains non-compliant with the minimum MVPHS requirement as of May 9, 2023. It has a separate compliance deadline of November 6, 2023, to regain MVPHS compliance or face potential delisting.
Outlook, Risks, and Management Commentary
Management states that operations are not affected by the Nasdaq notification and that ADSs will continue to trade. The company intends to monitor the bid price and may consider available options to regain compliance. If the company fails to meet the MVPHS requirement by November 6, 2023, it plans to request a hearing before a Nasdaq Hearings Panel to stay delisting actions. Significant risks include the potential loss of Nasdaq listing, the uncertainty of clinical trial outcomes for pipeline candidates, and the need for additional financing.
Investor Verification Checklist
- Verify the current closing bid price of RDHL ADSs to assess progress toward the $1.00 threshold.
- Confirm the company's status regarding the Market Value of Publicly Held Shares (MVPHS) requirement and the November 6, 2023, deadline.
- Review the company's cash position in recent filings (e.g., Form 20-F) to evaluate its ability to fund operations and potential reverse stock splits or capital raises.
- Monitor for any announcements regarding a hearing request with the Nasdaq Hearings Panel if MVPHS compliance is not achieved by November 2023.